Purpose: Ophthalmic beta-blockers, used in the treatment of increased intraocular pressure, are known to cause pulmonary adverse effects. Few, if any, studies have quantified the extent of the problem in a real-life population. In this nationwide study, we assess the pulmonary safety of patients initiating treatment with ophthalmic beta-blockers. Methods: Using the Danish Nationwide Registries from 1995 to 2012, we identified all individuals aged 20-90 years who initiated monotherapy with an intraocular pressure-lowering drug, with or without concomitant obstructive pulmonary disease. Risks of (i) switching to another drug and (ii) new onset of obstructive pulmonary disease during a 90-day follow-up were examined by cumulative risk and logistic regression models adjusted for available covariates. Results: The cohort consisted of 97 463 individuals. Odds ratios for drug switch in individuals without concomitant obstructive pulmonary disease (n = 86 568) were as follows: 1.47 for beta-blockers (95% confidence interval (CI): 1.35-1.61; p < 0.001), 2.68 for parasympathomimetics (95% CI: 2.32-3.10; p < 0.001) and 4.80 for alfa-2-agonists (95% CI: 4.17-5.53; p < 0.001). Odds ratios in individuals with concomitant obstructive pulmonary disease (n = 10 895) were as follows: 2.61 for parasympathomimetics (95% CI: 1.83-3.72; p < 0.001), 2.96 for beta-blockers (95% CI: 2.31-3.78; p < 0.001) and 3.54 for alfa-2-agonists (95% CI: 2.56-4.88; p < 0.001). There was no significant association between treatment class and new onset of obstructive pulmonary disease (p = 0.30). Conclusion: Ophthalmic beta-blockers were associated with an increased risk of drug switch. However, the absolute risk was very small. No increased risk of new onset of obstructive pulmonary disease was found. Our data suggest that more patients might be eligible for ophthalmic beta-blockers.
Introduction
Ophthalmic beta-blockers have been used for several decades as intraocular pressure-lowering drugs in the treatment of several ophthalmological diseases, most commonly open-angle glaucoma. However, their usage is widely debated because of the inherent risk of pulmonary adverse effects originating from bronchoconstriction due to systemic uptake.
It is estimated that more than 70 million people worldwide are affected by glaucoma (Weinreb et al. 2014) , and it is suggested that almost 4% of Danish citizens above the age of 50 years suffer from glaucoma and as much as 10% of those older than 80 years (Kolko et al. 2015) . Increased intraocular pressure has been identified as the most important risk factor for the development of glaucomatous optic neuropathy (Braunger et al. 2015) , making intraocular pressure-lowering drugs an essential part of the treatment. These include beta-blockers, alfa-2-agonists, carbonic anhydrase inhibitors, prostaglandin analogues and parasympathomimetics. They are all applied locally but are partially absorbed directly into the bloodstream, as approximately 80% is drained through the nasolacrimal duct and enter the systemic circulation through the highly vascularized nasal mucosa, thus preventing first-pass metabolism in the liver (Han et al. 2008 ). The nonselective beta-blocker timolol is one of the most effective first-line drugs in the treatment of increased intraocular pressure (Li et al. 2016) , however, activation of beta-adrenoceptors in the bronchial tree might cause systemic adverse effects (Vander Zanden et al. 2001; Lama 2002; Han et al. 2008 ) and consequently, many practitioners are reluctant to prescribe it.
Numerous studies have shown an association between ophthalmic betablockers and bronchoconstriction but these are mostly small-scale trials and, to our knowledge, the actual extent of the problem has not yet been quantified in a population-based cohort. The aim of this nationwide study of 97 463 patients was to investigate the pulmonary safety of ophthalmic betablockers compared with other intraocular pressure-lowering drugs.
Subjects and Methods

Databases
The study is a retrospective cohort study using Danish Nationwide Registries. All Danish residents are at birth assigned a permanent, unique civil registration number which allows direct linkage of data from all the different nationwide registers. Drug prescription information was obtained through the Danish National Register for Medicinal Statistics, which includes all dispensed prescriptions from Danish pharmacies since 1995 classified according to the Anatomical Therapeutic Chemical system (ATC). As the healthcare system is state financed and partly reimburses drug costs, the Danish pharmacies are obligated by law to register all dispensed prescriptions, which provides an accurate and valid register (Kildemoes et al. 2011) . The Danish National Patient Registry was used to gather information on hospital admissions with diagnoses registered according to the International Classification of Diseases (ICD), 8th and 10th revision. Date of birth and date of death were obtained through the Danish Civil Registration System.
Aims and study population
The main outcomes of the study were as follows: (i) The risk of switch from one intraocular pressure-lowering drug to another in a 90-day follow-up period in patients with or without concomitant obstructive pulmonary disease, respectively, and (ii) the risk of receiving a first-ever diagnosis of/ treatment for an obstructive pulmonary disease in a 90-day follow-up period compared to prostaglandin analogues.
International Classification of Diseases (ICD) and Anatomical Therapeutic Chemical (ATC) codes were used to identify relevant diagnoses and prescription patterns as described in the following. Intraocular pressurelowering drugs; Alfa-2-agonists (ATC: S01EA), parasympathomimetics (ATC: S01EB), carbonic anhydrase inhibitors (ATC: S01EC), beta-blocking agents (ATC: S01ED) and prostaglandin analogues (ATC: S01EE). Individuals were considered as having an obstructive pulmonary disease if at least two prescriptions for a drug used for obstructive pulmonary disease (ATC: R03) were instigated within 90 days, or if at least one hospital admission with a diagnosis of an obstructive pulmonary disease or acute respiratory failure (ICD-8: 490-493 and 783. ICD-10: J40-J47, J96 and J99) was observed.
Data on the study population originated from registries based on data collected between 1995 and 2012. Patients in the age between 20 and 90 years were included at the time of initiation of monotherapy with an intraocular pressure-lowering drug and were followed until whichever came first of one of the following: The outcome of interest occurred, the end of the follow-up period (31 December 2012) or the individual died.
Statistical analyses
Based on initial prescription of pressurelowering drugs, patients were divided into five different groups: Beta-blockers, prostaglandin analogues, carbonic anhydrase inhibitors, alfa-2-agonists and parasympathomimetics. Prostaglandin analogues were used as reference for statistical analyses because it is currently the most commonly used drug and there is no suspicion of increased risk of respiratory side-effects.
Results were adjusted for age at treatment start, gender and season of treatment start.
In addition, the following conditions present before the date of initial treatment were included in the analysis, and results were adjusted accordingly: hypertension, cardiovascular disease and cardiac arrhythmias.
Cumulative risk curves were plotted for the five classes of pressure-lowering drugs to illustrate trends in drug switch and new onset of obstructive pulmonary disease. Logistic regression models were used to determine the risks of switching drug and receiving first-ever diagnosis of or treatment for obstructive pulmonary disease, respectively. Odds ratios (OR) represent the relative risks, with confidence 95% intervals. p-values <0.05 were considered significant. Statistical analyses were performed using SAS Enterprise Guide (version 6.1, SAS Institute, Cary, NC, USA) and R statistical software (RStudio Team (2015) . RStudio: Integrated Development for R (Version 0.99.902). RStudio, Inc., Boston, MA URL http://www.rstudio. com/).
Ethics
This study was approved by the Danish Data Protection Agency, approval number GEH-2014-014, I-suite:02732. Ethical approval is not required for register-based studies in Denmark.
Results
Demographics
Presented in Table 1 are the general baseline characteristics of the study population, divided into the five different classes of intraocular pressurelowering treatment. Between 1995 and 2012, a total of 97 463 individuals at the age 20-90 years initiated monotherapy with an intraocular pressurelowering drug. The study population consisted of 56% women and 44% men with a mean age of 66.2 (standard deviation (SD) AE 14.9) years. In total, 11.2% of the patients had a concomitant obstructive pulmonary disease.
Analyses
Risk of drug switch Individuals without obstructive pulmonary disease. Figure 1 presents the cumulative risk curves for drug switch in patients without obstructive pulmonary disease (n = 28 210). In the alfa-2-agonist treatment group, 281 (11.9%) patients switched drugs within a 90-day follow-up period. In the betablocker treatment group, 1124 (4.0%) patients switched drugs in the follow-up period. In the carbonic anhydrase inhibitor treatment group, 472 (2.4%) patients switched drugs. In the parasympathomimetics treatment group, 249 (7.2%) patients switched drugs. Lastly, in the prostaglandin analogue treatment group, 923 (2.8%) patients switched drugs. Figure 2 presents the results of the multivariable analysis. Concomitant cardiac arrhythmia, treatment start in winter or fall and age between 50 and 70 years were risk factors for drug switch, whereas male gender had a protecting effect. After adjusting for available confounders, the odds ratios of drug switch (using prostaglandin analogues as reference) were 1.47 for beta-blockers (95% confidence interval (CI): 1.35-1.61; p < 0.001), 2.68 for parasympathomimetics (95% CI: 2.32-3.10; p < 0.001), 4.80 for alfa-2-agonists (95% CI: 4.17-5.53; p < 0.001) and 0.89 for carbonic anhydrase inhibitors (95% CI: 0.79-1.00; p = 0.05).
Individuals with concomitant obstructive pulmonary disease. Figure 3 presents the cumulative risk curves for drug switch in patients with concomitant obstructive pulmonary disease (n = 1550). In the alfa-2-agonist treatment group, 54 (9.2%) patients switched drugs within a 90-day follow-up period. In the beta-blocker treatment group, 122 (7.9%) patients switched drugs in the follow-up period. In the carbonic anhydrase inhibitor treatment group, 93 (3.4%) patients switched drugs. In the parasympathomimetics treatment group, 42 (7.2%) patients switched drugs. Lastly, in the prostaglandin analogue treatment group, 157 (2.9%) patients switched drugs. Figure 4 presents the results of the multivariable analysis. Treatment start in the winter was a risk factor for drug switch, whereas male gender had a protecting effect. After adjusting for available confounders, the odds ratios of drug switch (using prostaglandin analogues as reference) were 2.61 for parasympathomimetics (95% CI: 1.83-3.72; p < 0.001), 2.96 for beta-blockers (95% CI: 2.31-3.78; p < 0.001) and 3.54 for alfa-2-agonists (95% CI: 2.56-4.88; p < 0.001). No significantly increased risk of drug switch was found for carbonic anhydrase inhibitors with an odds ratio of 1.23 (95% CI: 0.95-1.60; p = 0.12).
Risk of getting diagnosis of/treatment for obstructive pulmonary disease Figure 5 presents the cumulative risk curves for the risk of getting a first-ever diagnosis of/treatment for obstructive pulmonary disease (n = 74 437). In the alfa-2-agonist treatment group, 15 (0.74%) patients received a first-ever diagnosis of/treatment for obstructive pulmonary disease within a 90-day follow-up period. In the beta-blocker treatment group, this was the case for 164 (0.65%) patients. In the carbonic anhydrase inhibitor treatment group, the case for 98 (0.59%) patients. In the parasympathomimetics treatment group, the case for 16 (0.54%) patients. Lastly, in the prostaglandin analogue treatment group, it was the case for 143 (0.52%) patients. No significant differences were found between the treatment groups, regarding the risk of receiving a first-ever diagnosis of/treatment for obstructive pulmonary disease (p = 0.30).
Discussion
This nationwide study found that ophthalmic beta-blockers were associated with a significantly increased risk of drug switch compared with prostaglandin analogues. We demonstrated a 50% increased risk in patients without concomitant obstructive pulmonary disease (p < 0.001) and a tripled risk in patients with concomitant obstructive pulmonary disease (p < 0.001). However, the absolute risk of drug switch was~4% for patients without obstructive pulmonary disease and 8% for patients with obstructive pulmonary disease. Thus, >90% of patients that initiated treatment with ophthalmic beta-blockers, with or without concomitant obstructive pulmonary disease, did not switch treatment. For all other treatment classes, the risk of drug switch was roughly the same whether the patients had a concomitant obstructive pulmonary disease or not. Furthermore, looking at the cumulative risk curves (Figure 3) , it seems that patients in the beta-blocker treatment group with concomitant obstructive pulmonary disease switched drugs earlier in the follow-up period. These findings suggest that patients with concomitant obstructive pulmonary We also found significantly increased odds ratios for drug switch in patients who initiated intraocular pressurelowering treatment with alfa-2-agonists or parasympathomimetics. This could be attributed to the fact that these are second-and third-line choices of treatment, respectively, that are primarily given when there are contraindications against beta-blockers and prostaglandin analogues. They are generally associated with more ocular irritation and often need to be administered 3-4 times daily, which could cause an increased risk of drug switch. Furthermore, parasympathomimetics are no longer prescribed as monotherapy and, consequently, these data are from an older time period, which could confound the result. Lastly, very few people initiated treatment with alfa-2-agonists or parasympathomimetics compared with beta-blockers, carbonic anhydrase inhibitors and prostaglandin analogues. No significant difference in the risk of new onset of obstructive pulmonary disease was found regardless of the drug used to initiate treatment. Only 0.7% of patients with ophthalmic betablockers received a first-ever diagnosis of or treatment for obstructive pulmonary disease in the 90-day followup. This is in discrepancy with a British retrospective cohort study by Kirwan et al. (2004) demonstrating increased risk of getting a first-ever prescription for a drug specifically used in the management of airway obstruction for selective beta-blockers of 3.0 (95% CI: 1.6-5.4) and an increased risk for unselective beta-blockers of 2.2 (95% CI: 1.6-3.0). However, the study differed largely from ours methodologically: the population was smaller with 324 individuals treated with selective betablockers and 2321 individuals treated with nonselective beta-blockers, follow-up times were unfixed and control groups were unexposed.
It should be noted that elderly patients sometimes have a certain degree of unrecognized obstructive pulmonary disease, which they do not necessarily subjectively notice (Connolly et al. 1992; Diggory et al. 1993) . Hence, some patients might not see a doctor, and we could thus underestimate the problem. Also, patients with chronic obstructive pulmonary disease do not generally have the same degree of bronchial hyperreactivity as do asthmatics (Lama 2002) , and as we did not distinguish between these, there is a possibility of overlooking a particularly harmful effect in asthmatics. However, the risk may diminish if the asthma is well treated. In accordance with our study, a retrospective cohort study by Huerta et al. (2001) found that use of ophthalmic beta-blockers was not associated with an increased risk of neither asthma nor chronic obstructive pulmonary disease.
Study limitations
A general limitation for any type of observational registry-based study is the risk of contamination in the target population by other diseases. Diagnoses captured in the Danish Health Registries are generally reliable, but when classifying by medication patterns, there is an assumption that drugs are used appropriately by both doctors and patients. Consequently, there is a risk of misclassification. We tried minimizing the risk of misclassification by defining obstructive pulmonary disease using both diagnoses and medications. Regarding glaucoma treatment, the pressure-lowering drugs are relatively glaucoma-specific, which reduces the risk of misclassification. However, conditions such as uveitis and eye trauma can also result in increased intraocular pressure. This is of minor importance, although, as we wanted to investigate the effects of the drugs per se and not specifically patients with glaucoma.
The Danish Health Registries contain valid and uniquely detailed information, which allows an extraction of data on concomitant diseases and medications. The factors available in the registries that we considered possible confounders were included in the multivariable analysis, yet, a possible effect of unmeasured confounders cannot be excluded.
Another limitation of the study comes from the lack of information on the cause of drug switch. Furthermore, it is only possible to assess those adverse effects severe enough to lead to drug switch or the receiving of a diagnosis of/treatment for obstructive pulmonary disease.
Given the follow-up period of 90 days, we know nothing of events potentially occurring after this cut-off. We cannot exclude that a certain threshold for intolerance is reached after this time, however, any systemic adverse reactions should occur readily after administration (Lama 2002) , and an extension of follow-up time to 180 days did indeed not alter the results markedly. Lastly, observational type studies, like this, can show correlations but never prove causality.
In conclusion, patients that initiated intraocular pressure-lowering treatment with ophthalmic beta-blockers had a significantly higher risk of switching to another drug, especially patients with concomitant obstructive pulmonary disease. However, the absolute risk was very small. We also found alfa-2-agonists and parasympathomimetics to be associated with a higher risk of drug switch. We did not find ophthalmic beta-blockers to be associated with an increased risk of receiving first-ever diagnosis or treatment for obstructive pulmonary disease. Generally, most of the research in this field comprise of small-scale trials, most of which emphasize the potentially detrimental effects of ophthalmic beta-blockers on pulmonary safety (Schoene et al. 1981; Weinreb et al. 1988; Diggory et al. 1993 Diggory et al. , 1995 Diggory et al. , 1998 Waldock et al. 2000) , both in patients with concomitant obstructive pulmonary disease and in patients without known susceptibility (Han et al. 2008 ). However, our findings suggest that, from a clinical perspective, the problem in a real-life population is limited and that more patients might be eligible for ophthalmic beta-blockers as antiglaucomatous treatment, also patients with well-treated concomitant obstructive pulmonary disease.
